Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404 · see citing works

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · see citing works

β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1× · see citing works

Phases of Aβ-deposition in the human brain and its relevance for the development of AD

Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · see citing works

Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859 · see citing works

Amyloid β-peptide is produced by cultured cells during normal metabolism

Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · see citing works

Purification and cloning of amyloid precursor protein β-secretase from human brain

Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612 · see citing works

Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438 · see citing works

Cleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor

Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,403 · see citing works

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080 · see citing works

Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex

De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · see citing works

The Pathogenesis of Senile Plaques

DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753 · see citing works

The prevalence and causes of dementia in people under the age of 65 years

Harvey, R. J. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1206 · Cited by 650 · see citing works

The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway

Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592 · see citing works

The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function pathogenic mechanism.

Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · see citing works

Relative Abundance of Alzheimer A Beta Amyloid Peptide Variants in Alzheimer Disease and normal Aging

Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468 · see citing works

beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms.

Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B., & Selkoe, D. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53650-4 · Cited by 465 · see citing works

Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro

Pike, C. J., Overman, M. J., & Cotman, C. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23895 · Cited by 302 · see citing works

Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease

Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., Little, S. P., & Ball, M. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78080-6 · Cited by 223 · see citing works

Molecular genetics of Alzheimer's disease: An update

Brouwers, N., Sleegers, K., & Broeckhoven, C. V. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 208 · see citing works

Amyloid β Protein Starting Pyroglutamate at Position 3 Is a Major Component of the Amyloid Deposits in the Alzheimer's Disease Brain

Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202 · see citing works

β-Amyloid Is Different in Normal Aging and in Alzheimer Disease

Piccini, A., Russo, C., Gliozzi, A., Relini, A., Vitali, A., Borghi, R., Giliberto, L., Armirotti, A., D’Arrigo, C., Bachi, A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501694200 · Cited by 193 · see citing works

A novel pathway for amyloid precursor protein processing

Portelius, E., Price, E. A., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., Brinkmalm, A., Zetterberg, H., Simon, A. J., & Blennow, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.06.002 · Cited by 169 · see citing works

Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains

Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B. G., & Tjernberg, L. O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06170.x · Cited by 147 · see citing works

Characterization of Amyloid β Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry

Portelius, E., Tran, A. J., Andréasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K., & Brinkmalm, A. (2007) · Journal of Proteome Research · doi:10.1021/pr0703627 · Cited by 146 · see citing works

Amino-Terminally Truncated Aβ Peptide Species Are the Main Component of Cotton Wool Plaques

Miravalle, L., Calero, M., Takao, M., Roher, A. E., Ghetti, B. F., & Vidal, R. (2005) · Biochemistry · doi:10.1021/bi0508237 · Cited by 140 · see citing works

The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid

Lalowski, M. M., Golabek, A. A., Lemere, C. A., Selkoe, D. J., Wı́sniewski, H. M., Beavis, R. C., Frangione, B., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 134 · see citing works

Generation and Regulation of β‐Amyloid Peptide Variants by Neurons

Gouras, G. K., Xu, H., Jovanovic, J. N., Buxbaum, J. D., Wang, R., Greengard, P., Relkin, N. R., & Gandy, S. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71051920.x · Cited by 122 · see citing works

Chromosome 14–encoded Alzheimer's disease: Genetic and clinicopathological description

Haltia, M., Viitanen, M. H., Sulkava, R. O., Ala‐Hurula, V., Pöyhönen, M., Goldfarb, L. G., Brown, P., Levy, E., Houlde, H., Crook, R., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410360307 · Cited by 98 · see citing works

Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family

Lannfelt, L., Bogdanović, N., Appelgren, H., Axelman, K., Lilius, L., Hansson, G. K., Schenk, D., Hardy, J., & Winblad, B. G. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90463-4 · Cited by 89 · see citing works

Aspects of β-Amyloid as a Biomarker for Alzheimer's Disease

Andréasson, U., Portelius, E., Andersson, M. E., Blennow, K., & Zetterberg, H. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.1.59 · Cited by 74 · see citing works

α‐secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generation

Jäger, S., Leuchtenberger, S., Martin, A. M., Czirr, E., Wesselowski, J., Dieckmann, M., Waldron, E., Korth, C., Koo, E. H., Heneka, M. T., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06420.x · Cited by 73 · see citing works

Identification of Novel APP/Aβ Isoforms in Human Cerebrospinal Fluid

Portelius, E., Brinkmalm, G., Tran, A. J., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2009) · Neurodegenerative Diseases · doi:10.1159/000203774 · Cited by 71 · see citing works

The role of proteomics in dementia and Alzheimer’s disease

Zellner, M., Veitinger, M., & Umlauf, E. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0502-7 · Cited by 54 · see citing works

Prospective neuropsychological assessment of nondemented patients with biopsy proven senile plaques

Mackenzie, I. R., McLachlan, R. S., Kubu, C. S., & Miller, L. A. (1996) · Neurology · doi:10.1212/wnl.46.2.425 · Cited by 32 · see citing works

Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease

Portelius, E., Zhang, B., Gustavsson, M. K., Brinkmalm, G., Brinkmalm, A., Zetterberg, H., Lee, V. M. ‐., Trojanowski, J. Q., & Blennow, K. (2009) · Neurodegenerative Diseases · doi:10.1159/000264639 · Cited by 29 · see citing works

APOE polymorphism and clinical duration determine regional neuropathology in Swedish APP670, 671 mutation carriers: implications for late‐onset Alzheimer's disease

Bogdanović, N., Corder, E. H., Lannfelt, L., & Winblad, B. G. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00187.x · Cited by 29 · see citing works

Commentary: Aβ N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology

Tekirian, T. L. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3209 · Cited by 28 · see citing works

Alzheimer's disease

Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 339 · see citing works

γ-Secretase in Alzheimer’s disease

Hur, J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 325 · see citing works

The role of metallobiology and amyloid-β peptides in Alzheimer's disease

Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L., & Duce, J. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07500.x · Cited by 266 · see citing works

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266 · see citing works

Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress

Garza-Lombó, C., Posadas, Y., Quintanar, L., Gonsebatt, M. E., & Franco, R. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7272 · Cited by 254 · see citing works

Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease

McColl, G., Roberts, B., Pukala, T., Kenche, V., Roberts, C., Link, C., Ryan, T., Masters, C., Barnham, K., Bush, A., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-57 · Cited by 256 · see citing works

Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β-peptides in human cerebrospinal fluid

Halim, A., Brinkmalm, G., Rüetschi, U., Brinkmalm, A., Portelius, E., Zetterberg, H., Blennow, K., Larson, G., & Nilsson, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102664108 · Cited by 247 · see citing works

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234 · see citing works

Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease

Rasmussen, J., Mahler, J., Beschörner, N., Kaeser, S. A., Häsler, L. M., Baumann, F., Nyström, S., Portelius, E., Blennow, K., Lashley, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713215114 · Cited by 228 · see citing works

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

Jawhar, S., Wirths, O., & Bayer, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.288308 · Cited by 220 · see citing works

Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice

Stöhr, J., Condello, C., Watts, J. C., Bloch, L., Oehler, A., Nick, M., DeArmond, S. J., Giles, K., DeGrado, W. F., & Prusiner, S. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408968111 · Cited by 173 · see citing works

Pathways to Alzheimer's disease

Hardy, J., Bogdanović, N., Winblad, B. G., Portelius, E., Andreasen, N. C., Cedazo-Mı́nguez, Á., & Zetterberg, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12192 · Cited by 177 · see citing works

N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits

Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., Lefebvre, T., Sprenger, F., Wirths, O., Zweckstetter, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1129-2 · Cited by 175 · see citing works

Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain

Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-10422-x · Cited by 164 · see citing works

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease

Bayer, T. A., & Wirths, O. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1287-x · Cited by 168 · see citing works

Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PET

Roberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143 · see citing works

Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

Bayer, T. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 141 · see citing works

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136 · see citing works

A Functional Role for Aβ in Metal Homeostasis? N‐Truncation and High‐Affinity Copper Binding

Mital, M., Wezynfeld, N. E., Frączyk, T., Wiloch, M. Z., Wawrzyniak, U. E., Bonna, A., Tumpach, C., Barnham, K. J., Haigh, C. L., Bal, W., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502644 · Cited by 132 · see citing works

Distinct deposition of amyloid-β species in brains with Alzheimer’s disease pathology visualized with MALDI imaging mass spectrometry

Kakuda, N., Miyasaka, T., Iwasaki, N., Nirasawa, T., Wada‐Kakuda, S., Takahashi‐Fujigasaki, J., Murayama, S., Ihara, Y., & Ikegawa, M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0477-x · Cited by 130 · see citing works

The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease

Tan, J. Z. A., & Gleeson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.11.013 · Cited by 126 · see citing works

Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice

López‐González, I., Schlüter, A., Aso, E., Garcia‐Esparcia, P., Ansoleaga, B., Llorens, F., Carmona, M., Moreno, J. R., Fuso, A., Portero‐Otín, M., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000176 · Cited by 125 · see citing works

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 122 · see citing works

Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease

Pera, M., Alcolea, D. A., Sánchez‐Valle, R., Guardia‐Laguarta, C., Colom‐Cadena, M., Badiola, N., Suárez‐Calvet, M., Lladó, A., Barrera-Ocampo, A. A., Falla, D. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1062-9 · Cited by 120 · see citing works

APP/Aβ structural diversity and Alzheimer's disease pathogenesis

Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., Sabbagh, M., & Beach, T. G. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.007 · Cited by 121 · see citing works

Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 71 · see citing works

Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer’s brain

Brinkmalm, G., Hong, W., Wang, Z., Liu, W., O’Malley, T. T., Sun, X., Frosch, M. P., Selkoe, D. J., Portelius, E., Zetterberg, H., et al. (2019) · Brain · doi:10.1093/brain/awz066 · Cited by 114 · see citing works

Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid-β Load and Cognitive Decline in Alzheimer's Disease

Morawski, M., Schilling, S., Kreuzberger, M., Waniek, A., Jäger, C., Koch, B. M., Cynis, H., Kehlen, A., Arendt, T., Hartlage‐Rübsamen, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131535 · Cited by 114 · see citing works

Biomarkers in Sporadic and Familial Alzheimer’s Disease

Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106 · see citing works

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease

Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105 · see citing works

Mammalian Metallothionein-3: New Functional and Structural Insights

Vašák, M., & Meloni, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061117 · Cited by 105 · see citing works

Overexpression of Glutaminyl Cyclase, the Enzyme Responsible for Pyroglutamate Aβ Formation, Induces Behavioral Deficits, and Glutaminyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice

Jawhar, S., Wirths, O., Schilling, S., Graubner, S., Demuth, H., & Bayer, T. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.185819 · Cited by 105 · see citing works

The binding of resveratrol to monomer and fibril amyloid beta

Ge, J., Qiao, J., Qi, C., Wang, C.-W., & Zhou, J. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.012 · Cited by 105 · see citing works

Amyloid-β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease

Santos, A. N., Ewers, M., Minthon, L., Simm, A., Silber, R., Blennow, K., Prvulovic, D., Hansson, O., & Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111361 · Cited by 101 · see citing works

Alzheimer’s disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory

Klyubin, I. V., Cullen, W. K., Hu, N., & Rowan, M. J. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-25 · Cited by 101 · see citing works

Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation

Davis, R. C., Marsden, I. T., Maloney, M. T., Minamide, L. S., Podlisny, M. B., Selkoe, D. J., & Bamburg, J. R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-10 · Cited by 97 · see citing works

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

Bayer, T. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 98 · see citing works

Extracellular Vesicles in Alzheimer’s Disease: Friends or Foes? Focus on Aβ-Vesicle Interaction

Joshi, P., Benussi, L., Furlan, R., Ghidoni, R., & Verderio, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16034800 · Cited by 95 · see citing works

Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders

Hook, G., Reinheckel, T., Ni, J., Wu, Z., Kindy, M. S., Peters, C., & HOOK, V. Y. H. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000527 · Cited by 95 · see citing works

The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease

Drew, S. C. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00317 · Cited by 93 · see citing works

Advancements in Top-Down Proteomics

Zhou, H., Ning, Z., Starr, A. E., Abu‐Farha, M., & Figeys, D. (2011) · Analytical Chemistry · doi:10.1021/ac202882y · Cited by 94 · see citing works

Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimer’s Disease by Deep Sequencing

Bouter, Y., Kacprowski, T., Weißmann, R., Dietrich, K., Borgers, H., Brauß, A., Sperling, C., Wirths, O., Albrecht, M., Jensen, L. R., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00075 · Cited by 91 · see citing works

7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance

Akhtar, A., Dhaliwal, J., & Sah, S. P. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05826-7 · Cited by 89 · see citing works

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease

Brody, D. L., Jiang, H., Wildburger, N. C., & Esparza, T. J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0293-3 · Cited by 84 · see citing works

The missing link in the amyloid cascade of Alzheimer’s disease – Metal ions

Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 88 · see citing works

Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples

Watt, A. D., Perez, K. A., Rembach, A., Sherratt, N. A., Hung, L. W., Johanssen, T., McLean, C., Kok, W. M., Hutton, C. A., Fodero‐Tavoletti, M. T., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1083-z · Cited by 85 · see citing works

Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer’s Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry

Kaya, I., Zetterberg, H., Blennow, K., & Hanrieder, J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00121 · Cited by 87 · see citing works

Molecular subtypes of Alzheimer’s disease

Fede, G. D., Catania, M., Maderna, E., Ghidoni, R., Benussi, L., Tonoli, E., Giaccone, G., Moda, F., Paterlini, A., Campagnani, I., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21641-1 · Cited by 85 · see citing works

Aβ plaques

Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 95 · see citing works

Cell-type Dependent Alzheimer's Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability

Muratore, C., Zhou, C. Q., Liao, M., Fernandez, M. A., Taylor, W. M., Lagomarsino, V. N., Pearse, R. V., Rice, H. C., Negri, J. M., He, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.015 · Cited by 82 · see citing works

Capping of Aβ42 Oligomers by Small Molecule Inhibitors

Fu, Z., Aucoin, D., Ahmed, M., Ziliox, M., Nostrand, W. E. V., & Smith, S. O. (2014) · Biochemistry · doi:10.1021/bi500910b · Cited by 85 · see citing works

Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons

Gunn, A. P., Wong, B. X. W., Johanssen, T., Griffith, J. C., Masters, C. L., Bush, A. I., Barnham, K. J., Duce, J. A., & Cherny, R. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655183 · Cited by 84 · see citing works

Brain Pyroglutamate Amyloid-β is Produced by Cathepsin B and is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic

Hook, G., Yu, J., Toneff, T., Kindy, M. S., & HOOK, V. Y. H. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131370 · Cited by 82 · see citing works

Mechanism of Nucleated Conformational Conversion of Aβ42

Fu, Z., Aucoin, D., Davis, J., Nostrand, W. E. V., & Smith, S. O. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00467 · Cited by 83 · see citing works

First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression

Cummings, D. M., Liu, W., Portelius, E., Bayram, S., Yasvoina, M. V., Ho, H., Smits, H., Ali, S. S., Steinberg, R., Pegasiou, C.-M., et al. (2015) · Brain · doi:10.1093/brain/awv127 · Cited by 81 · see citing works

Pyroglutamate-Aβ: Role in the natural history of Alzheimer's disease

Gunn, A. P., Masters, C. L., & Cherny, R. A. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.08.015 · Cited by 79 · see citing works

Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model

Hüttenrauch, M., Brauß, A., Kurdakova, A., Borgers, H., Klinker, F., Liebetanz, D., Salinas-Riester, G., Wiltfang, J., Klafki, H. W., & Wirths, O. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.65 · Cited by 78 · see citing works

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy

Hoffmann, T., Meyer, A., Heiser, U. F., Kurat, S., Böhme, L., Kleinschmidt, M., Bühring, K. U., Hutter‐Paier, B., Farcher, M., Demuth, H., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240614 · Cited by 78 · see citing works

Microglia and amyloid plaque formation in Alzheimer's disease – Evidence, possible mechanisms, and future challenges

Fruhwürth, S., Zetterberg, H., & Paludan, S. R. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578342 · Cited by 75 · see citing works

Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease

Wittnam, J. L., Portelius, E., Zetterberg, H., Gustavsson, M. K., Schilling, S., Koch, B. C. P., Demuth, H., Blennow, K., Wirths, O., & Bayer, T. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308601 · Cited by 77 · see citing works

Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid

Fritschi, S. K., Langer, F., Kaeser, S. A., Maia, L. F., Portelius, E., Pinotsi, D., Kaminski, C. F., Winkler, D. T., Maetzler, W., Keyvani, K., et al. (2014) · Brain · doi:10.1093/brain/awu255 · Cited by 78 · see citing works

Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models

Wirths, O., & Zampar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218144 · Cited by 75 · see citing works

18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4–42 Model of Alzheimer’s Disease

Bouter, C., Henniges, P., Franke, T., Irwin, C., Sahlmann, C., Sichler, M., Beindorff, N., Bayer, T., & Bouter, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00425 · Cited by 58 · see citing works

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology

Michno, W., Nyström, S., Wehrli, P. M., Lashley, T., Brinkmalm, G., Guérard, L., Syvänen, S., Sehlin, D., Kaya, I., Brinet, D., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006604 · Cited by 73 · see citing works

A comparative analysis of the aggregation behavior of amyloid‐β peptide variants

Vandersteen, A., Hubin, E., Sarroukh, R., Baets, G. D., Schymkowitz, J. W. H., Rousseau, F., Subramaniam, V., Raussens, V., Wenschuh, H., Wildemann, D., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.10.022 · Cited by 74 · see citing works

Analysis of Motor Function in the Tg4-42 Mouse Model of Alzheimer’s Disease

Wagner, J. M., Sichler, M. E., Schleicher, E. M., Franke, T. N., Irwin, C., Löw, M. J., Beindorff, N., Bouter, C., Bayer, T. A., & Bouter, Y. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00107 · Cited by 74 · see citing works

Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies

Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 97 · see citing works

Alzheimer’s amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood‐brain barrier integrity, and angiogenesis

Parodi‐Rullán, R. M., Ghiso, J. A., Cabrera, E., Rostagno, A. A., & Fossati, S. (2020) · Aging Cell · doi:10.1111/acel.13258 · Cited by 70 · see citing works

BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System

Mattsson, N., Rajendran, L., Zetterberg, H., Gustavsson, M. K., Andréasson, U., Olsson, M., Brinkmalm, G., Lundkvist, J., Jacobson, L. H., Perrot, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031084 · Cited by 70 · see citing works

The coexistence of an equal amount of Alzheimer's amyloid‐β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway

Chang, Y., & Chen, Y. (2014) · FEBS Journal · doi:10.1111/febs.12813 · Cited by 68 · see citing works

A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer’s disease

Gkanatsiou, E., Portelius, E., Toomey, C. E., Blennow, K., Zetterberg, H., Lashley, T., & Brinkmalm, G. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.033 · Cited by 66 · see citing works

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use

d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 68 · see citing works

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET

van Westen, D., Lindqvist, D., Blennow, K., Minthon, L., Nägga, K., Stomrud, E., Zetterberg, H., & Hansson, O. (2016) · Scientific Reports · doi:10.1038/srep20709 · Cited by 66 · see citing works

The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease

Walter, S., Jumpertz, T., Hüttenrauch, M., Ogorek, I., Gerber, H., Storck, S. E., Zampar, S., Dimitrov, M., Lehmann, S., Lepka, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1929-5 · Cited by 65 · see citing works

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms

Hartlage‐Rübsamen, M., Morawski, M., Waniek, A., Jäger, C., Zeitschel, U., Koch, B. C. P., Cynis, H., Schilling, S., Schliebs, R., Demuth, H., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0806-2 · Cited by 66 · see citing works

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy

Pérez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65 · see citing works

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Wirths, O., Walter, S., Kraus, I., Klafki, H., Stazi, M., Oberstein, T. J., Ghiso, J. A., Wiltfang, J., Bayer, T. A., & Weggen, S. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0309-z · Cited by 65 · see citing works

β‐Secretase‐1 elevation in aged monkey and Alzheimer’s disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β‐amyloid accumulation

Cai, Y., Xiong, K., Zhang, X., Cai, H., Luo, X., Feng, J., Clough, R. W., Struble, R. G., Patrylo, P. R., Chu, Y., et al. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07376.x · Cited by 64 · see citing works

Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases

Walker, L. C. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-120215-034943 · Cited by 59 · see citing works

Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease

Hartlage‐Rübsamen, M., Waniek, A., Meißner, J., Morawski, M., Schilling, S., Jäger, C., Kleinschmidt, M., Cynis, H., Kehlen, A., Arendt, T., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1395-2 · Cited by 61 · see citing works

Designed Metal-ATCUN Derivatives: Redox- and Non-redox-Based Applications Relevant for Chemistry, Biology, and Medicine

Maiti, B. K., Govil, N., Kundu, T., & Moura, J. J. G. (2020) · iScience · doi:10.1016/j.isci.2020.101792 · Cited by 62 · see citing works

Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease

Helmfors, L., Boman, A., Civitelli, L., Nath, S., Sandin, L., Janefjord, C., McCann, H., Zetterberg, H., Blennow, K., Halliday, G. M., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.024 · Cited by 61 · see citing works

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports · doi:10.1038/srep17338 · Cited by 61 · see citing works

Resistance of Cu(Aβ4–16) to Copper Capture by Metallothionein‐3 Supports a Function for the Aβ4–42 Peptide as a Synaptic CuII Scavenger

Wezynfeld, N. E., Stefaniak, E., Stachucy, K., Drozd, A., Płonka, D., Drew, S. C., Krężel, A., & Bal, W. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511968 · Cited by 60 · see citing works

GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology

Michno, W., Wehrli, P. M., Zetterberg, H., Blennow, K., & Hanrieder, J. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.09.010 · Cited by 59 · see citing works

Search strategy analysis of Tg4-42 Alzheimer Mice in the Morris Water Maze reveals early spatial navigation deficits

Curdt, N., Schmitt, F. W., Bouter, C., Iseni, T., Weile, H. C., Altunok, B., Beindorff, N., Bayer, T. A., Cooke, M. B., & Bouter, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-09270-1 · Cited by 55 · see citing works

N-truncated Abeta starting with position four: Early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody

Antonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-56 · Cited by 53 · see citing works

Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals Aβ Aggregation Dependent Anionic Lipid Accumulations and Metabolism

Michno, W., Kaya, I., Nyström, S., Guérard, L., Nilsson, K. P. R., Hammarström, P., Blennow, K., Zetterberg, H., & Hanrieder, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01361 · Cited by 53 · see citing works

CuII Binding Properties of N-Truncated Aβ Peptides: In Search of Biological Function

Stefaniak, E., & Bal, W. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b01399 · Cited by 53 · see citing works

Mass Spectrometric Characterization of Amyloid-β Species in the 7PA2 Cell Model of Alzheimer's Disease

Portelius, E., Olsson, M., Brinkmalm, G., Rüetschi, U., Mattsson, N., Andréasson, U., Gobom, J., Brinkmalm, A., Hölttä, M., Blennow, K., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120994 · Cited by 50 · see citing works

Brain Amyloid-Beta Fragment Signatures in Pathological Ageing and Alzheimer's Disease by Hybrid Immunoprecipitation Mass Spectrometry

Portelius, E., Lashley, T., Westerlund, A., Persson, R., Fox, N. C., Blennow, K., Révész, T., & Zetterberg, H. (2015) · Neurodegenerative Diseases · doi:10.1159/000369465 · Cited by 50 · see citing works

Cu II Binding to Various Forms of Amyloid‐β Peptides: Are They Friends or Foes?

Borghesani, V., Aliès, B., & Hureau, C. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201700776 · Cited by 49 · see citing works

Dynamic micellar oligomers of amyloid beta peptides play a crucial role in their aggregation mechanisms

Morel, B., Carrasco, M. P., Jurado, S., Marco, C., & Conejero‐Lara, F. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp02685h · Cited by 49 · see citing works

Probing amyloid‐β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry

Carlred, L., Michno, W., Kaya, I., Sjövall, P., Syvänen, S., & Hanrieder, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13645 · Cited by 44 · see citing works

Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease

Giesers, N. K., & Wirths, O. (2020) · ASN Neuro · doi:10.1177/1759091420925356 · Cited by 47 · see citing works

Statistically quantified measurement of an Alzheimer's marker by surface‐enhanced Raman scattering

Buividas, R., Dzingelevičius, N., Kubiliūtė, R., Stoddart, P. R., Truong, V. K., Ivanova, E. P., & Juodkazis, S. (2014) · Journal of Biophotonics · doi:10.1002/jbio.201400017 · Cited by 47 · see citing works

Sequence proximity between Cu(II) and Cu(I) binding sites of human copper transporter 1 model peptides defines reactivity with ascorbate and O2

Schwab, S. K., Shearer, J., Conklin, S. E., Aliès, B., & Haas, K. L. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.12.021 · Cited by 47 · see citing works

Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings

Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46 · see citing works

The Pathogenic Ab43 Is Enriched in Familial and Sporadic Alzheimer Disease

Anna, S., Wel, H., Winblad, B., Graff, C., & Tjernberg, L. O. (2012)

The Pathogenic Aβ43 Is Enriched in Familial and Sporadic Alzheimer Disease

Matton, A., Welander, H., Winblad, B. G., Graff, C., & Tjernberg, L. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055847 · Cited by 69 · see citing works

Distribution of isomerized and racemized amyloid β isoforms in sporadic Alzheimer’s disease using ion‐mobility mass spectrometry

Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.039256

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

Portelius, E., Andréasson, U., Ringman, J. M., Büerger, K., Daborg, J., Buchhave, P., Hansson, O., Harmsen, A., Gustavsson, M. K., Hanse, E., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-2 · Cited by 94 · see citing works

Isomerized Aβ in the brains can distinguish the status of amyloidosis in the Alzheimer’s Disease continuum

Mukherjee, S., Dubois, C., Perez, K. A., Birchall, I. E., Hinton, F., McLean, C. A., Masters, C. L., & Roberts, B. R. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.090569